Characteristic Facial Changes in Cyclosporine Patients
The characteristic facial features in patients on cyclosporine include gingival hyperplasia, hypertrichosis (excessive facial hair growth), sebaceous hyperplasia, and acne-like eruptions, with less common but documented abnormal facial bone growth patterns in pediatric patients.
Primary Cutaneous Manifestations
Gingival Hyperplasia
Gingival hyperplasia is a well-recognized facial change with cyclosporine therapy 1. This risk increases when cyclosporine is combined with calcium channel blockers (particularly nifedipine), which are commonly prescribed to manage cyclosporine-induced hypertension 1. The combination creates an additive effect on gingival tissue proliferation.
Hypertrichosis and Hirsutism
Hypertrichosis occurs in approximately 19% of dermatology patients and 6.6% of psoriasis patients treated with cyclosporine 1, 2. This manifests as:
- Excessive facial hair growth
- Darkening of existing hair
- Can appear as early as 6 days after treatment initiation, though typically develops between 45 days to 4 months 3
- Affects both male and female patients 3
Sebaceous Hyperplasia
Sebaceous hyperplasia is frequently observed during cyclosporine treatment 1. The characteristic presentation includes:
- Yellowish or skin-colored papules with central umbilication
- Telangiectasia on the surface
- Predominantly affects the face (cheeks, forehead, temples)
- Occurs in approximately 10% of cyclosporine-treated patients 4
- More common in males around age 40, though can occur in younger patients 4
- Results from cyclosporine increasing sebum secretion and 5-alpha reductase enzyme activity 5
Treatment with isotretinoin (0.6 mg/kg/day) has shown near-complete regression within 2 months 5.
Acne and Follicular Changes
Cyclosporine is strongly associated with acne and acne-like eruptions 1. Related phenomena include:
- Severe acne forms
- Folliculitis
- Keloid development
- Acne keloidalis of the scalp
- Hyperplastic pseudofolliculitis barbae
Pediatric Facial Bone Growth Abnormalities
In pediatric patients, cyclosporine can induce abnormal facial bone growth patterns 6. Cephalometric studies demonstrate:
- Shortening of posterior facial height
- Increased anterior facial height with deep mandibular plane angle
- Absolute shortening of mandibular body
- Mandibular retrognathia (receding lower jaw)
- Inhibition of mandibular condylar growth
These changes primarily affect the lower third of the face and were documented in 8 of 9 pediatric renal transplant recipients receiving cyclosporine 6.
Additional Facial Manifestations
Hyperpigmentation
Generalized hyperpigmentation is a rare but documented side effect 3. While typically occurring 45 days to 4 months after initiation, cases have been reported as early as 6 days post-treatment 3.
Neurological Facial Effects
Rare cases of peripheral facial paralysis have been reported, particularly when associated with hypomagnesemia 7. This may not resolve with drug cessation.
Clinical Monitoring Recommendations
Based on guideline recommendations 1:
- Perform baseline physical examination documenting facial features
- Monitor for cutaneous side effects at each visit
- Consider dose reduction if cosmetically significant changes develop
- Evaluate serum magnesium levels if neurological symptoms appear
- In pediatric patients, consider monitoring facial growth patterns with prolonged therapy
Important Caveats
The cutaneous manifestations are generally dose-related and may improve with dose reduction 1. However, structural changes (particularly pediatric bone growth abnormalities) may not be fully reversible 6. When calcium channel blockers are needed for hypertension management, be aware of the increased risk of gingival hyperplasia 1.